Cowen Starts Dicerna Pharmaceuticals (DRNA) at Outperform

Cowen initiates coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Outperform rating.

Analyst Ritu Baral commented, "We are initiating on DRNA with an Outperform based on their proprietary differentiated RNAi platform, which we believe can rapidly generate promising RNAi candidates with significant market potential in rare diseases and oncology. We think DRNAs Dicer candidates already have POC from Alnylam's RNAi success, but may have differentiated therapeutic profiles."

For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.

Shares of Dicerna Pharmaceuticals closed at $10.93 yesterday.

You May Also Be Interested In

• B.Riley Starts Suncrete Inc (RMIX) at Buy
• TD Cowen Reiterates Buy Rating on argenx SE (ARGX)
• Leerink Starts Quince Therapeutics Inc. (QNCX) at Outperform